WHO report is ‘major step forward’ in fight against drug-resistant bacteria

A new report by the World Health Organization lays out, for the first time, which antibiotic-resistant bacteria pose the greatest risk to global health and urgently need new effective treatments.

The report was chaired by Prof. Evelina Tacconelli, executive committee member of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the WHO and with input from several ESCMID experts.

The WHO Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics report is targeted at pharmaceutical companies, research institutions and policy-makers around the world. It is part of broader efforts to tackle the rising tide of infections that have become resistant to the drugs commonly used to treat them.

Prof. Tacconelli said: “Antibiotic-resistant infections have a major impact on patients’ quality of life and are associated with high death rates.

“Modern medicine relies on antibiotics to treat infections and to prevent them in high risk patients. This includes transplant recipients or those affected by cancer, as well as in patients receiving common procedures such hip-replacements and Caesarean sections. However, the current pipeline of antibiotics is almost empty.

“This report marks a major step forward in identifying which bacteria pose the greatest risk for patient care because of a lack of effective treatments. We hope that it will drive governments and research groups working in antibiotic development to set the right research priorities that will reduce the burden of antibiotic-resistant infections globally.”

The report categorizes bacteria into ‘critical’, ‘high’ and ‘medium’ priority groups. The bacteria listed as in need of urgent treatment solutions include *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and Enterobacteriaceae which are resistant to multiple antibiotics and responsible for severe infections such as pneumonia and sepsis, mainly in hospitalised patients.

Resistant bacteria that also affect healthy people outside hospitals are included in the “high” priority group. These include methicillin-resistant *Staphylococcus aureus* (MRSA), *Salmonella* (responsible for food-poisoning) and *Neisseria gonorrhoeae* (the sexually transmitted bacteria responsible for gonorrhoea).

The development of the list has been achieved through an extensive review of the evidence and surveillance data from all WHO regions. It includes existing databases from guidelines such as the those developed by ESCMID [1] on reducing the spread of multidrug resistant Gram-negative bacteria in hospitalised patients.
The coordinating group of this project included other experts active in the ESCMID network: Prof. Gunnar Kahlmeter from ESCMID’s European Committee on Antimicrobial Susceptibility Testing (EUCAST), and Prof. Jan Kluytmans, Prof. Céline Pulcini and Dr Ursula Theuretzbacher who are actively involved in ESCMID’s study groups and are programme committee members for the ESCMID annual conference (ECCMID, European Congress of Clinical Microbiology and Infectious Diseases).

Ends

Further information:

Kerry Noble

Mobile: +44 (0) 7446 869 433

Email: kerry.noble@tbicommunications.com

Notes to Editors

The report URL, when it goes live, will be: http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/

About the European Society of Clinical Microbiology and Infectious Diseases

ESCMID is a non-profit organization dedicated to improving the diagnosis, treatment and prevention of infectious diseases in Europe and beyond. The society promotes and supports research, education and training and shares good medical practice in infection-related disciplines with a special focus on antimicrobial resistance to build capacity throughout the world. www.escmid.org


http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)60007-0